Enliven Therapeutics, Inc.
ELVN
$19.69
-$0.70-3.43%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.17M | 5.81M | 5.78M | 4.72M | 3.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.90M | 27.07M | 24.60M | 24.69M | 21.43M |
| Operating Income | -26.90M | -27.07M | -24.60M | -24.69M | -21.43M |
| Income Before Tax | -23.18M | -23.16M | -19.72M | -22.74M | -19.37M |
| Income Tax Expenses | 0.00 | -- | 232.00K | -- | -- |
| Earnings from Continuing Operations | -23.18M | -23.16M | -19.95M | -22.74M | -19.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.18M | -23.16M | -19.95M | -22.74M | -19.37M |
| EBIT | -26.90M | -27.07M | -24.60M | -24.69M | -21.43M |
| EBITDA | -26.82M | -26.99M | -24.53M | -24.61M | -21.35M |
| EPS Basic | -0.46 | -0.48 | -0.42 | -0.54 | -0.47 |
| Normalized Basic EPS | -0.30 | -0.30 | -0.26 | -0.32 | -0.27 |
| EPS Diluted | -0.46 | -0.48 | -0.42 | -0.54 | -0.47 |
| Normalized Diluted EPS | -0.30 | -0.30 | -0.26 | -0.32 | -0.27 |
| Average Basic Shares Outstanding | 49.86M | 48.27M | 48.08M | 42.05M | 41.13M |
| Average Diluted Shares Outstanding | 49.86M | 48.27M | 48.08M | 42.05M | 41.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |